With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
FAST NEWS: Vaccine Maker Jiangsu Recbio Gets Little Boost on Listing Day
The latest: Jiangsu Recbio Technology Co. Ltd (2179.HK), a producer of human papillomavirus (HPV) vaccines, received a muted reception as it made its trading debut in Hong Kong on Thursday.…
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK -
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
- Sunho Biologics gets green light for downsized IPO
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
